- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03369756
Prontosan Quality of Life Study in Patients With Chronic Leg Wound(s)
A Prospective Study of Quality of Life in Patients With Chronic Leg Wound(s) Treated With Prontosan® Wound Irrigation Solution and Prontosan® Wound Gel
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Jupiter, Florida, United States, 33458
- Jupiter Medical Center
-
North Miami Beach, Florida, United States, 33169
- Barry University Clinical Research
-
-
New York
-
N. New Hyde Park, New York, United States, 11042
- Northwell Comprehensive Wound Care Healing Center and Hyperbarics
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, United States, 18015
- St. Luke's Wound Care Center
-
Harrisburg, Pennsylvania, United States, 17112
- Harrisburg Foot and Ankle Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female ≥18 years of age
- Either 2 wounds on 1 leg or 1 wound on each leg or only 1 wound. Wound(s) must be located below the knee.
- At least one wound must have a surface area ≥5 cm2 and ≤50 cm2 and it also must be present for ≥4 weeks
- Mean global score ≥1.18 on the Wound-QoL questionnaire (this will be calculated by the electronic data capture [EDC] system at the time of screening to assess eligibility)
- Willingness to wear an off-loading device if medically indicated (e.g., DH shoe or walker)
Exclusion Criteria:
- Prior treatment with Prontosan solution or Prontosan gel on the wound(s)
- Infection in the wound(s)
- Cartilage exposure in the wound(s)
- Antibiotic therapy within 7 days prior to baseline (i.e., prior to first administration of study treatment). Topical antibiotics not applied to the wound are acceptable.
- Current diagnosis of severe peripheral artery disease as indicated by clinical findings (i.e., no palpable pulse on both dorsal pedis and posterior tibial arteries of the affected limb) or an Ankle Brachial Index of < 0.5
- Presence of gangrene in the wound(s) or on the leg(s)
- Active (flare up) rheumatic or collagen vascular disease (including rheumatoid arthritis, scleroderma, and systemic lupus erythematosus), psoriasis, sarcoidosis, or other skin disease. These subjects are allowed to receive oral, inhaled, or parenteral corticosteroids, immunosuppressive agents, or cytotoxic agents. Note: fibromyalgia is acceptable.
- Osteomyelitis diagnosed by x-ray, bone biopsy, or other radiological procedure within 90 days prior to the screening visit
- Active radiation therapy below the hip
- Subjects with medical conditions other then those identified in Exclusion Criteria 7 who are currently receiving or has received oral, or parenteral corticosteroids, immunosuppressive agents, or cytotoxic agents within 30 days prior to baseline (i.e., prior to first administration of study treatment) or is anticipated to require such agents during the course of the study
- Clinical laboratory values that may impair wound healing; for example, hemoglobin <10 g/dL, or HbA1c ≥12%
- Enrolled in any investigational drug or device study for any disease/indication within 30 days prior to the screening visit
- Unable to comprehend or comply with study requirements, or inability to sign an informed consent form
- Allergic to any of the components in Prontosan solution or Prontosan gel
- Patients who, in the opinion of the Investigator, would not be suitable candidates for this study or have some impediment to their ability to heal
- Preplanned surgery or procedures that would occur during the study (other than deemed minor and clinically non-significant by the Investigator) or that would interfere with the study
- Phase 4 pressure ulcer as defined by full-thickness skin and tissue loss with exposed or directly palpable fascia, muscle, tendon, ligament, cartilage or bone in the ulcer. Slough and/or eschar may be visible
- Severe secondary lymphedema as diagnosed by clinical findings in inferior members (e.g., legs)
- A diagnosis of malnutrition as determined by either a low BMI (<18.5 kg/m2), or on the combined finding of weight loss together with reduced BMI (age-specific)
- Employee of the Investigator or study center, with direct involvement in the study or other studies under the direction of that Investigator or study center, as well as family members of the employees or the Investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Prontosan Solution and Gel
Treatment with Prontosan® Wound Irrigation Solution and Prontosan® Wound Gel over 4 week period
|
Wound cleansing using Prontosan solution and gel
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wound-QoL Global Score
Time Frame: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
|
The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess "Body", "Psyche" and "Everyday Life". These subscales cover items 1 to 16. Item 17 is not part of any of the subscales. The Wound-QoL can be used in clinical and observational studies and in daily practice. Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). A "Total" or "Global" score is the average of at least 13 completed questions, regardless of which questions were not completed. The average of each of the 3 subscales can be computed if no more than 1 item of the subscale is missing. The higher values represents more of an impact to the patient for that item. |
5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wound QoL Subscore; Body Dimension
Time Frame: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
|
The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess "Body", "Psyche" and "Everyday Life". It can be used in clinical and observational studies and in daily practice. Subscale "Body" consists of Items #1 to #5. Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). The average of the subscale can be computed if no more than 1 item of the subscale is missing. The higher values represents more of an impact to the patient for that item. |
5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
|
Wound QoL Subscore; Psyche Dimension
Time Frame: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
|
The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess "Body", "Psyche" and "Everyday Life". It can be used in clinical and observational studies and in daily practice. Subscale "Psyche" consists of Items #Items #6 to #10. Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). The average of the subscale can be computed if no more than 1 item of the subscale is missing. The higher values represents more of an impact to the patient for that item. |
5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
|
Wound QoL Subscore; Everyday Life Dimension
Time Frame: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
|
The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess "Body", "Psyche" and "Everyday Life". It can be used in clinical and observational studies and in daily practice. Subscale "Everyday Life" consists of Items #Items #11 to #16. Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). The average of the subscale can be computed if no more than 1 item of the subscale is missing. Generally, the higher values represents more of an impact to the patient for that item. |
5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wound Size
Time Frame: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
|
Change in wound size from Baseline/Week 1 to Final/Week 5.
The change in the size of a wound will be evaluated using a disposable ruler to directly measure the overall wound dimensions at each scheduled visit to the study site (Weeks 1 and 5).
These measurements will be done before any cleaning of the wound and after cleaning the wound (debridement).
|
5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Richmond NA, Maderal AD, Vivas AC. Evidence-based management of common chronic lower extremity ulcers. Dermatol Ther. 2013 May-Jun;26(3):187-96. doi: 10.1111/dth.12051.
- Frykberg RG, Banks J. Challenges in the Treatment of Chronic Wounds. Adv Wound Care (New Rochelle). 2015 Sep 1;4(9):560-582. doi: 10.1089/wound.2015.0635.
- McCarty SM, Percival SL. Proteases and Delayed Wound Healing. Adv Wound Care (New Rochelle). 2013 Oct;2(8):438-447. doi: 10.1089/wound.2012.0370.
- Leaper DJ, Schultz G, Carville K, Fletcher J, Swanson T, Drake R. Extending the TIME concept: what have we learned in the past 10 years?(*). Int Wound J. 2012 Dec;9 Suppl 2(Suppl 2):1-19. doi: 10.1111/j.1742-481X.2012.01097.x.
- Romanelli M, Dini V, Barbanera S, Bertone MS. Evaluation of the efficacy and tolerability of a solution containing propyl betaine and polihexanide for wound irrigation. Skin Pharmacol Physiol. 2010;23 Suppl:41-4. doi: 10.1159/000318266. Epub 2010 Sep 8.
- Andriessen AE, Eberlein T. Assessment of a wound cleansing solution in the treatment of problem wounds. Wounds. 2008 Jun;20(6):171-5.
- Blome C, Baade K, Debus ES, Price P, Augustin M. The "Wound-QoL": a short questionnaire measuring quality of life in patients with chronic wounds based on three established disease-specific instruments. Wound Repair Regen. 2014 Jul-Aug;22(4):504-14. doi: 10.1111/wrr.12193.
- Augustin M, Baade K, Herberger K, et al. Use of the Wound-QoL instrument in routine practice: feasibility, validity, and development of an implementation tool. Wound Medicine. 2014;5:4-8
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPM-G-H-1506
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wound of Lower Leg (Physical Finding)
-
Brigham and Women's HospitalWithdrawnWound of Knee | Wound of Skin | Non-melanoma Skin Cancer | Skin Graft Complications | Wound of Lower LegUnited States
-
3MWithdrawnLower Extremity Diabetic Leg Wounds | Lower Extremity Venous Leg Wounds | Lower Extremity Mixed Aetiology Leg WoundsUnited Kingdom
-
Sheffield Hallam UniversitySheffield Teaching Hospitals NHS Foundation TrustCompletedVirtual Reality | Lower Limb Injury | Paediatric | Physical RehabilitationUnited Kingdom
-
Hacettepe UniversityCompletedBurn Scar | Burns | Lower Limb Injury | Lower Limb WoundTurkey
-
SerenaGroup, Inc.Sanara MedTechActive, not recruiting
-
Tufts Medical CenterNot yet recruitingAtrophy of Rectus Femoris Muscle (Physical Finding)
-
University Hospital, MontpellierSociété Française de Médecine Vasculaire (SFMV)CompletedPeripheral Arterial Disease | Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer)France
-
Abeer MusaddiqCompletedOpen Wound of Lower LimbPakistan
-
National Taiwan Sport UniversityCompletedInjury of Multiple Muscles and Tendons at Lower Leg LevelTaiwan
-
Major Extremity Trauma Research ConsortiumNot yet recruitingWound Heal | Wound Complication | Wound Dehiscence | Fracture of Tibia | Infected Wound
Clinical Trials on Prontosan Wound Irrigation Solution and Prontosan Wound Gel
-
B. Braun Ltd. Centre of Excellence Infection ControlCompletedVenous Leg UlcerUnited Kingdom
-
The First Hospital of Jilin UniversityFujian Medical University Union Hospital; Shenzhen Second People's HospitalRecruitingBurns | Diabetic Foot Ulcer | Chronic Wound | Pressure Injury | Irrigation SolutionChina
-
Associazione Infermieristica per lo studio delle...B. Braun Medical SACompletedPressure Ulcer | Wound Cleansing | Chronic Wound CareItaly
-
Georgetown UniversityCompletedWound InfectionUnited States
-
Calvary Hospital, Bronx, NYB. Braun Medical SACompletedWound Care | Venous Ulcer Care | Wound Cleansing | Chronic Wound CareUnited States
-
University of Nevada, Las VegasRecruitingColorectal Disorders | Surgical Site Infection | Wound SurgicalUnited States
-
Wake Forest University Health SciencesRecruitingSpinal Cord Injuries | Pressure InjuriesUnited States
-
B. Braun Ltd. Centre of Excellence Infection ControlCompleted
-
SoftOx Solutions ASUnknown
-
Rochal Industries LLCThe University of Texas Health Science Center at San Antonio; Brooke Army Medical... and other collaboratorsNot yet recruiting